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Abstract
A novel recombinant protein tetra-H2A (TH) derived from histone H2A has been developed to 
replace protamine as a conditionally reversible, nucleic acid condensing agent. The novel protein 
will address the insufficient release of nucleic acid therapeutics, which is captured by protamine 
for siRNA delivery. TH is composed of 4 tandem repeats of the histone H2A N-terminal sequence, 
intervened by the cathepsin D cleavage site. The repeating H2A sequence enhances the binding 
affinity to anionic nucleic acids, forming more stable condensates, as demonstrated by the binding 
affinity assay. The TH/siRNA condensates are formulated into a core-membrane structured 
liposomal nanoparticle (NP). The endosomes of cancer cells are rich in cathepsin D, allowing on-
site degradation of TH and facilitating the intracellular release of siRNA. The NPs assembled with 
TH produced a higher silencing efficiency of target genes in vitro and in vivo than the NPs 
assembled with protamine as the nucleic acid condensing agent. The exploitation of TH in the NP 
formulation exhibited a biocompatibility profile similar to that of protamine, with minimal 
immunostimulating and systemic toxicity observed after repeated administration.
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1. Introduction
RNA interference (RNAi), discovered by Fire and Mello, had a strong impact on therapeutic 
drug development [1]. In particular, short-interference RNA (siRNA) can knockdown the 
target gene with high specificity and efficiency. Although the number of RNAi-related patent 
applications has skyrocketed, the systemic delivery of these vulnerable and negatively 
charged macromolecules to target cells remains an obstacle to clinical applications of RNAi 
therapy [2]. The advent of a versatile platform that can be easily tailored to target different 
cell populations and optimize the performance of various siRNA-based therapeutics is in 
high demand.
Nanoparticulate devices for drug delivery confer multiple advantages over free drugs, 
mainly through the improvement of their pharmacokinetics. Liposome-based formulations of 
anticancer drugs are examples of this strategy. The carriers are biodegradable, biologically 
inert, minimally immunogenic and readily modifiable for targeting purposes. Over the past 
few years, our group has been dedicated to the development of a series of PEGylated, 
liposome-based nanoparticles (NPs) that can efficiently deliver siRNA [3–6], pDNA [7], 
peptides [8], chemodrugs [9], and proteins [10] to solid tumors and metastatic lesions. In our 
Liposome-Protamine-Hyaluronic acid (LPH) formulation, the mix of anionic hyaluronic 
acid (HA) and siRNA is usually condensed into a nanometric complex using protamine-a 
naturally existing, arginine-rich polypeptide. The complex is then coated with lipids and 
extensively PEGylated [4]. The utilization of protamine as the condensing agent of nucleic 
acids enables the formation of a stable core that supports an oppositely charged lipid bilayer. 
However, the DNA condensing capacity of protamine is so strong that it does not readily 
release the nucleic acid cargo intracellularly, compromising the bioavailability of the 
delivered cargo.
In nature, protamines are replacements for histone proteins in the haploid phase of 
spermatogenesis [11], generating a more condensed packaging of genomic DNA and 
protecting the genetic message delivered by spermatozoa [12]. After fertilization, the highly 
packed nucleoprotamine complex is decondensed to allow the assembly of the nucleosome 
structure by histone proteins [13, 14]. The wisdom of nature inspired us to use a histone, a 
natural nucleic acid condensing reagent, with a weaker binding affinity, as a replacement for 
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protamine in our formulation. The arginine rich nuclear proteins, histone proteins [15–18] 
and histone protein derivatives [19, 20], have been extensively investigated as transfection 
reagents in vitro and in vivo. However, histone-mediated gene transfer resulted in relatively 
low transgene expression possibly due to insufficient condensation and/or endosome escape 
[21]. We attempted to address such issues by constructing a histone-based recombinant 
protein with protein engineering technology based on rational design.
In this study, we investigated the possibility of replacing protamine with a recombinant 
protein that was composed of four tandem repeats of human histone H2A peptide [19, 22], 
intervened by cathepsin D cleavage sites [22–24]. A pH-responsive membrane-lytic peptide, 
namely GALA [25], was incorporated into the C-terminal of the recombinant protein so as 
to facilitate the endosome escape of the cargo. We hypothesized that the recombinant 
protein, tetra-H2A (TH), was able to condense HA and siRNA into a stable complex that 
could support a cationic lipid coating and a high degree of PEGylation, forming Lipid-tetra-
H2A-Hyaluronic acid (LHH) NP, as illustrated in Fig 3a. The distal end of the PEG chain 
was conjugated with anisamide (AA) to target cancer cells that overexpress sigma receptor. 
Once the NP was taken up by the cells through receptor-mediated endocytosis, the cathepsin 
D cleavage sites in the TH were subject to enzymatic digestion in the endosome 
compartment as pH decreased. The degradation of the condensing agent was supposed to 
enhance the cytoplasmic release of nucleic acid cargos. The current study was designed to 
test these hypotheses. The delivery efficiency of the LHH NP was examined in NCI-H460, a 
human lung carcinoma cell line that overexpresses the sigma receptor [3, 5]. This cell line 
was also stably transduced with firefly luciferase gene, which allows convenient evaluation 
of the knockdown efficiency of the target gene through a luciferase assay.
2. Materials and Methods
2.1. Cell line and culture conditions
A human lung carcinoma cell line, NCI-H460 (ATCC, Manassas, VA) was cultured in 
RPMI-1640 supplemented with 10% fetal bovine serum (Life Technologies, Carlsbad, 
California), and penicillin/streptomycin (Life Technologies, Carlsbad, California). The H460 
cells were stably transduced with GL3 firefly luciferase genes with a retroviral vector to 
create H460 cells (H460-luc) that express luciferase by Pilar Blancafort’s laboratory at the 
University of North Carolina at Chapel Hill.
2.2. Cloning, expression and purification of TH
Gene encoding TH and TH mutants were synthesized by Blue Heron Biotech (Bothell, WA). 
The gene was cloned into a pET28b vector (Merck KGaA, Germany). The fidelity of the 
gene was confirmed using DNA sequencing. pET28b vectors with corresponding TH genes 
were transformed into BL21 (DE3) E. Coli expression host cell line (Merck KGaA, 
Germany). The transformant colony was grown in Circlegrow® media (MP Biomedicals, 
Solon, OH). The protein expression was induced with 0.6 mM ITPG (Fermentas, Glen 
Burnie, MD) at 30°C for 4h. Culture was centrifuged and lysed with a lysis buffer (100 mM 
NaH2PO4, 10 mM Tris, 500 mM NaCl, 1% Triton and 1 mM β-mercaptoethanol). The target 
protein contained Histidine x6 tag at the N-terminal. The lysate was spun at 30,000 xg for 45 
Wang et al. Page 3













min and the supernatant was loaded onto a 1 mL Ni-NTA agarose column (Qiagen, Valencia, 
CA) in the presence of 5 mM imidazole. The column was then washed with 20 mL wash 
buffer (100 mM NaH2PO4, 10 mM Tris, 500 mM NaCl, 20 mM imidazole and 1mM β-
mercaptoethanol). Protein was eluted with 5 mL elution buffer (100 mM NaH2PO4, 10 mM 
Tris, 500 mM NaCl, 200 mM imidazole and 1 mM β-mercaptoethanol). The protein was 
then desalted and buffer-exchanged using ultrafiltration with 3k Ultracel (Merck KGaA, 
Germany). The final protein was solubilized in 50 mM HEPES buffer (pH 7.0). The purity 
of the TH was examined by SDS-PAGE. The identity of the TH was also confirmed by 
western blot analysis by probing Histidine x6 tag.
2.3. Preparation of LHH NPs
1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP) (Avanti Polar Lipids Inc., Alabaster, 
Alabama) and cholesterol (1:1, mol:mol) (Sigma Aldrich, St. Louis, MO) were dissolved in 
chloroform and the solvent was removed under reduced pressure. The lipid film was 
hydrated overnight with distilled water to form cationic liposomes (10 mM), which were 
sequentially extruded through 400, 200, and 100 nm polycarbonate membranes (Millipore, 
Billerica, MA). The core of LHH-NPs was prepared by mixing 28 µg of TH in 100 µL 
deionized (DI) water with 10 µg of a mixture of HA and siRNA (1:1, w:w) in 100 µL DI 
water so that the N/P ratio between TH and the HA/siRNA mixture was approximately 
2.5:1, where N equals the positive charges carried by amine groups and P equals the negative 
charges carried by nucleic acid. To prepare the core of Lipid Protamine-HA (LPH)-NPs, 8 
µg of protamine in 100 µL DI water was complexed with 10 µg of a mixture of hyaluronic 
acid and siRNA (1:1, w:w) so that the N/P ratio was 1:1. After incubation at room 
temperature for 10 min, the core was mixed with 9 µL cationic liposome (20 mM) and 
incubated for another 10 min for lipid coating. The lipid-coated NPs were PEGylated using a 
post-insertional approach by adding 7 µL micelles (3.5mM) composed of DSPE-PEG and 
DSPE-PEG-AA (1:1; mol:mol) and incubating the NPs at 50°C for 15 min. DSPE-PEG-AA 
was synthesized in Dr. Leaf Huang’s laboratory based on a previously established protocol 
[26]. The size and zeta potential of the NPs were characterized using a Malvern Zetasizer 
ZS90 (Worcestershire, UK).
2.4. SYBR Green exclusion assay
SYBR Green I nucleic acid stain (Life Technologies, Carlsbad, California) was incubated 
with plasmid DNA (2 µg/mL) in TAE buffer according to the manufacturer’s instructions. 
One microgram of plasmid was then complexed with protamine (Sigma Aldrich, St. Louis, 
MO), H2A peptide (peptide2.0, Chantilly, VA) or TH at various N/P ratios. The complexes 
were incubated at room temperature for 15 min before measurement. The fluorescence of 
SYBR Green was determined using a PerkinElmer fluorescence spectrometer LS55 
(PerkinElmer Inc., Waltham, MA).
2.5. Cathepsin D cleavage digestion
Ten micrograms of the TH with or without cathepsin D cleavage sites were incubated with 2 
units of human liver cathepsin D (EMD Millipore, Billerica, MA) in the presence of 50 mM 
acetate buffer (pH 3.8) at 37°C. The digestion products were then resolved by 4–12% SDS-
PAGE (Life Technologies) and visualized using Coomassie staining.
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To quantify the Cathepsin D mediated digestion of polycations and the resulting release of 
nucleic acids, complexes were made by mixing five micrograms SYBR Green treated 
plasmid DNA with TH (2.5: 1 N/P ratio), TH/ΔCathD (2.5: 1 N/P ratio), H2A peptide (2.5: 1 
N/P ratio) or protamine (1:1 N/P ratio). These complexes were incubated with 2 units of 
cathepsin D in the presence of 50 mM acetate buffer (pH 3.8) at 37°C. Samples were 
assayed at different time points. The samples were neutralized by adding alkaline solution 
before the fluorescence intensity of SYBR Green was determined using a fluorescence 
spectrometer (PerkinElmer Inc.).
2.6. Hemolytic assay
The pH-responsive, membrane-lytic ability was determined using a hemolytic assay. Sheep 
red blood cells (RBC) (Innovative Research, Novi, MI) were washed thoroughly with DPBS 
and spun down at 1000 xg for 10 min. The RBCs were then reconstituted into 5×108 cells/ml 
at pH 5.0 or pH 7.4 with sodium phosphate/sodium acetate buffer (50 mM). Ten micrograms 
of TH or TH/ΔGALA were added to red blood cells with mild shaking (50 rpm) and 
incubated for 1 h at 37°C. The RBCs were then spun down at top speed with a tabletop 
centrifuge. The lysis of RBCs was determined by reading the absorbance of the supernatant 
at 541 nm using spectrometer (PerkinElmer Inc.).
2.7. In Vitro transfection and imaging
H460-luc cells stably transfected with luciferase genes were seeded in 96 wells with a 
seeding density of 5×103 cells/well. To demonstrate the targeted delivery of the NPs, siRNA 
against luciferase (target sequence 5′-CTT ACG CTG AGT ACT TCG A-3′) was 
encapsulated into LHH-NPs with or without AA, and added to the H460-luc cells at a final 
concentration of 50nM. To study the dose-response silencing effect, anti-luciferase siRNA 
was encapsulated into LHH-NPs prepared with TH, TH/ΔGALA, TH/ΔCathD and TH/
ΔGALA/ΔCathD. LPH-NP prepared with protamine was also used as a control. The NPs 
were administered to H460-luc cells so that the final concentration of siRNA was 5, 10, 25, 
50, 100, or 200 nM. After four hours of transfection, the NPs were removed and the medium 
was refreshed. The silencing of the luciferase genes was determined 24 h post-transfection 
using a luciferase assay kit (Promega, Madison, MI) following the manufacture’s 
instruction.
For in vitro imaging studies, 2×104 H460 cells were seeded in Lab-tek II 8-well chamber 
slides (Nalge Nunc International, Rochester, NY), Half a microgram of 6-carboxyfluorescein 
labeled double strand oligodeoxynucleotides (dsODN) (IDTDNA, Coralville, IA) was 
encapsulated into the LHH-NPs or LPH-NP and administered to the cells. The cells were 
then incubated with the NPs for 30 min before extensive washing with DPBS. To visualize 
the nuclei and lysosomes, the Hochest 33342 (Life Technologies) and LysoTracker (Life 
Technologies) were used to treat the cells for 30 min before observing according to the 
manufacturer’s instructions. The cells were imaged using an Olympus FV1000 multiphoton 
confocal microscope (Olympus America Inc) and images were analyzed with FV10-ASW 
Viewer3.1.
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2.8. In Vivo biodistribution study of LHH-NPs
Female athymic nude mice, 6–8 weeks old, were subcutaneously inoculated with 5×106 
H460 cells in the flank. LHH-NPs loaded with 10 µg of Texas Red labeled dsODN 
(IDTDNA, Coralville, IA) were prepared and injected intravenously (IV) into the tumor 
bearing mice. Four hours post-injection, animals were sacrificed and the organs were 
collected (heart, liver, spleen, lung, kidneys, tumor). Biodistribution of the labeled dsODN 
was qualitatively determined using a Kodak in vivo imaging system FX Pro (Rochester, 
NY). To quantify the in vivo biodistribution, ten micrograms of dsODN was labeled with 3H 
[27] and used to label LHH-NP. Major organs were collected 4 h post IV injection of 3H-
labeled LHH-NP. One-hundred grams of each tissue were treated with 1 mL NCS-II tissue 
solubilizer (GE Healthcare Biosciences, Pittsburgh, PA) overnight and heated at 50°C. 
Three-hundred microliters of the samples were then mixed with 4 mL Ultra Gold LSC-
Cocktail (Perkin Elmer Inc., Waltham, MA). The 3H reading was measured with a 
scintillation counter. All animal protocols were approved by the University of North 
Carolina at Chapel Hill’s Institutional Animal Care and Use Committee.
2.9. In Vivo target gene silencing mediated by LHH-NPs
In vivo transfection studies were conducted by formulating 10 µg anti-luciferase siRNA into 
LHH-NPs or LPH-NP and IV injecting the final particles into H460-luc xenograft bearing 
nude mice when the tumor size is about 200 mm3 (n=3). Mice were sacrificed 24 h post-
injection and tumor tissues were collected and homogenized. The tissue lysates were subject 
to luciferase assay (Promega, Madison, MI) according to the manufacturer’s instruction.
2.10. AST, ALT, BUN assay and cytokine induction assay
CD-1 mice (n=5) were IV injected with LHH-NPs (equivalent to 10 µg of dsODN) for three 
consecutive days. On day 4, mice were sacrificed and sera were prepared for AST, ALT and 
BUN assays performed by the UNC core facility. To evaluate the acute immune-stimulating 
property of the LHH-NPs, CD-1 mice (n=3) were sacrificed 4 h after injection with LHH-
NP or LPH-NP (equivalent to 10 µg of dsODN). Sera were collected from these mice for 
IL-6, IL-12, IFN-α and TNF-α level with ELISA assay kit (BD Biosciences, San Diego, 
CA) according to manufacturer’s manual.
3. Results
3.1. The recombinant protein TH was expressed and purified with high purity
Based on the repetition of histone H2A sequences in TH, the gene encoding TH was codon-
optimized for higher expression in E. coli. The gene was then commercially synthesized, 
cloned into pET28b vectors and transformed into the expression host strain, BL21(DE3). 
Expression was optimized using various ITPG induction concentrations at different 
temperatures. Induction of the protein with 0.6 mM IPTG at 30°C for 4 h produced the 
highest protein yield with the fewest degradation products. TH was purified under native 
conditions using Ni-NTA affinity chromatography by capturing the Hisx6 tag of the N-
terminal of TH. Purified TH was then buffer-exchanged with ultrafiltration. The final yield 
was approximately 5 mg per liter of culture. The purity of the TH was determined using a 
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SDS-PAGE followed by coomassie staining. The results indicated an estimated purity 
greater than 95% (Fig. 1b). The identity of the purified TH was confirmed by western blot 
analysis conducted with a monoclonal anti-Hisx6 tag antibody (Fig. 1c). To validate the 
functionality of each motif, a series of mutant THs that lack either one of or both GALA and 
cathepsin D cleavage sites were expressed and purified as controls (termed TH/ΔGALA, 
TH/ΔCathD and TH/ΔGALA/ΔCathD, respectively).
3.2. The placement of motifs maintains their individual functionalities in the TH
The accessibility of cathepsin D cleavage sites in the TH to their corresponding enzymes 
was examined using a digestion assay at the optimal reaction conditions of human cathepsin 
D. The TH was incubated with cathepsin D for 1 h and the digestion products were analyzed 
using SDS-PAGE. The densitometry analysis of the bands stained with coomassie blue 
indicated that there was 46% degradation of TH (Fig. 2a) after one-hour exposure to 
cathepsin D. The digestion products were approximately 4 KDa and 13 KDa, which 
corresponded to an H2A monomer and trimer (or dimer with GALA). Although the cleavage 
sites were incorporated into the recombinant protein for enhanced degradation, the 
accessibility of the sites to the enzyme was different in a molecule due to steric hindrance. If 
no cleavage sites were available, 90% of TH/ΔCathD remained intact after cathepsin D 
digestion (Fig. 2a). The minimal degradation of TH/ΔCathD was most likely due to non-
specific digestion after long-term incubation. Thus, the inclusion of cleavage sites responded 
to cathepsin D and facilated the degradation as expected.
A hemolysis assay was used to illustrate the pH-responsive, membrane lytic activity of the 
GALA peptide, which resides in the C-terminal region of TH. TH and TH/ΔGALA were 
incubated with sheep’s red blood cells at a neutral (pH 7.4) or acidic pH (pH 5.0). The 
hemolytic activities of the THs were quantified using the release of hemoglobin as 
determined by absorbance at 541nm. The results showed that the acidic pH activated the 
hemolytic activity of GALA in the C-terminal of the TH, which resulted in ~35% hemolysis. 
This activity, however, did not occur in neutral pH conditions (Fig. 2b). TH/ΔGALA, was a 
stringent control and did not induce hemolysis regardless of pH, ruling out the possibility 
that the lysis of the membrane was due to the multimerized H2A sequence. These results, 
combined with the results illustrating Cathepsin D digestion, demonstrate that both 
cathepsin D substrate and GALA peptide sequences have retained their designated 
functionality after incorporation into TH.
3.3. The incorporation of cathepsin D facilitates the release of nucleic acid cargo upon 
enzymatic digestion
It is observed that polycations with higher molecular weights, such as polyethyleneimine, 
polylysine and chitosan [28], have demonstrated higher binding affinity to the polyanionic 
nucleic acids. To enhance the binding affinity between the condensing agent and nucleic acid 
cargo, the histone H2A derived peptide was multimerized to increase the molecular weight. 
The DNA condensing capacity of the TH was assayed using a SYBR Green exclusion assay. 
The binding of SYBR Green to DNA strands increases the fluorescence intensity. This can 
be reversed through polycation-mediated DNA condensation because the process excludes 
the fluorescent probe. H2A peptide, protamine and TH were used to complex with plasmid 
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DNA (pDNA) pretreated with SYBR Green at various N/P ratios. The fluorescence intensity 
emitted by the complexes was measured. The activity of inducing pDNA condensation by 
TH was higher than that of the protamine; complete condensation of pDNA occurred at a 
higher N/P ratio for TH than protamine (2.5:1 vs. 1.5:1) (Fig. 2c). In contrast, H2A peptide 
had induced only a partial condensation even at very high N/P ratios. Thus, multimerization 
has indeed increased the binding affinity of H2A.
In order to study enzyme-triggered release profiles of the nucleic acid, the condensed pDNA 
by H2A, protamine, TH and TH/ΔCathD at the optimal N/P ratios were incubated with 
human cathepsin D enzyme. Protamine was used to condense pDNA at a 1:1 N/P ratio, 
while H2A peptide, recombinant TH or TH derivatives condensed pDNA at a 2.5:1 N/P 
ratio. An increase of the fluorescence intensity was observed in the TH condensed pDNA 
complex when incubated with the enzyme, indicating a loosened structure due to the 
degradation of biopolymer by cathepsin D (Fig. 2d). The fluorescence intensities of TH/
ΔCathD or protamine mediated condensation did not change in the presence of the enzyme 
at all the time points observed. Additionally, no significant change was observed in the TH/
pDNA complexes incubated with BSA, which suggested that the disassembly was not 
caused by charge-related competitive interaction.
3.4. The TH replaces protamine and forms highly PEGylated LHH NPs that targets sigma 
receptors to promote siRNA delivery
The optimization of the NP formulation (Fig. 3a) was performed with a series of 
characterization studies to sequentially determine the optimal ratios for core complexes, 
liposome coating and the degree of PEGylation (data not shown). The core of the NP was 
formed by electrostatic interactions between cationic TH and anionic HA/siRNA mixture. 
The optimum N/P ratio for forming the core complexes were 2.5:1 for TH or TH derivatives, 
and 1:1 for protamine, so that the HA/siRNA (or dsODN) was condensed to the highest 
degree, and yet the core complex possessed a negative surface charge. The negatively 
charged core complex was then coated with cationic liposomes and then PEGylated through 
post-insertion. The LHH-NP or LPH-NP used in the following experiments were prepared 
using the same protocol as that described here. The LHH-NPs were characterized using 
dynamic light scattering and Laser Doppler Velocimetry, regarding the physicochemical 
properties. The final NP was determined to be ~50nm in diameter and with a surface charge 
of ~15mV (Fig. 3b). The size and uniformity of the LHH NPs were further confirmed using 
transmission electron microscopy (TEM) after uranyl acetate staining (Fig. 3c).
In order to validate the targeting ability of the AA that was conjugated to the distal end of 
the PEG chain, siRNA against the luciferase gene was encapsulated into LHH-NPs with or 
without AA, and added to H460 cells that were stably expressing luciferase. The silencing 
efficiency was assayed 24 h post-transfection using a luciferase assay. The results 
demonstrated that the LHH-NP with AA resulted in ~75% knockdown of luciferase gene 
(Fig. 4a). In contrast, siRNA encapsulated into LHH-NP without AA resulted in only ~36% 
knockdown efficiency. The cytotoxicity of LHH-NP was also evaluated in H460 cells using 
a MTS assay. The dose dependent cytotoxicity data, together with the results of the dose 
dependent silencing assay demonstrated that even at an extremely high dose, 100 times 
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higher than the IC50 (4.3 nM), minimal cytotoxicity was observed in the cell cultures treated 
with LHH-NP (Fig. 4b).
3.5. The TH facilitated intracellular release of nucleic acid cargo, resulting in a higher 
efficiency of gene silencing
To study the influences of different condensing agents on the intracellular distribution of 
nucleic acids delivered by the NPs, a confocal microscopy study was conducted. The results 
demonstrated that FAM-labeled dsODNs (green) appeared in the cytoplasm 30 min after 
administration (Fig. 5a). Moreover, the dsODNs did not co-localize with LysoTracker (red) 
labeled lysosomes, which indicated an efficient endosome escape regardless of the 
condensing agent used. LHH-NP prepared with TH resulted in a homogenous intracellular 
distribution of FAM-labeled dsODNs. In contrast, dsODNs delivered by LHH/ΔCathD-NP 
(Fig. 5a-2) prepared with the TH/ΔCathD, or delivered by LPH-NP prepared with the 
protamine, showed a punctate distribution pattern (Fig. 5a-4). This suggested insufficient 
release of the cargo from the NPs, probably due to the lack of degradation mechanism of the 
condensing agent. Interestingly, the FAM-labeled dsODNs that were delivered by LHH/
ΔGALA-NP, prepared with TH/GALA, showed a homogenous distribution as well as an 
efficient endosomal escape. Since all NPs were coated with cationic liposomes composed of 
DOTAP/Cholesterol, the results suggested that the cationic lipid was the major driving force 
to destabilize the endosome membrane due to the ion-pair mechanism [29]. The qualitative 
imaging assay revealed that the GALA peptide only played a minor role in facilitating 
endosomal escape.
To evaluate the influences of various condensing agents on the knockdown efficiency of the 
NPs, anti-luciferase siRNA was formulated into the NPs and administered to H460-luc cells 
that were stably transfected with luciferase (Fig. 5b). Dose-response curves of different 
formulations were plotted using Prism software. The IC50, which indicates the dose required 
to achieve 50% knockdown of the target gene, was calculated. The IC50 for LHH-NP 
mediated transfection was about 4.3nM (Fig. 5c), which was 3 times lower than LPH-NP 
mediated transfection (13.1nM). Due to the lack of disassembly mechanism, the IC50 of 
siRNA delivered by LHH/ΔCathD was equivalent (13.2nM) to that of LPH. These data were 
in agreement with the results from confocal microscopic observations regarding to the 
release profiles.
3.6. Systemic administration of LHH-NP resulted in efficient target gene silencing
To study the in vivo biodistribution of the NPs after systemic administration, Texas-red 
labeled dsODN was encapsulated into LHH-NP and IV injected into H460-luc xenograft 
bearing nude mice. The tumor and major organs were harvested 4 h post-administration and 
the biodistribution of LHH-NP was determined using an in vivo imaging system. The result 
showed that the Texas-red labeled dsODN accumulated primarily in the tumors, with some 
deposits in the liver (Fig. 6a). Consistent with cell culture confocal microscopic data, there 
was a homogenous, intracellular distribution of Texas-red labeled dsODN in the cryosection 
of the tumor tissue. As was observed that fluorescence based imaging approach did not 
reflect the distribution quantitatively due to the quenching issues [30], 3H-labeled dsODNs 
were encapsulated into LHH-NP and IV injected to the xenograft bearing mice to accurately 
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quantify the biodistribution of the therapeutics delivered by LHH-NP. Based on the activity 
detected from the organs and tumors collected 4 h post-injection, there was ~5% injected 
dose per gram of tissue accumulated in the tumor (Fig 6c). The overall tumor accumulation 
of LHH-NP was not significantly different from that of LPH-NP, and was independent of the 
presence of AA as a targeting ligand (data not shown).
The in vivo efficiency of gene silencing by tumor-targeted siRNA was evaluated in H460-luc 
xenograft-bearing nude mice. Anti-luciferase siRNA was encapsulated into LHH and LPH 
NPs and IV injected into the mice. Twenty-four hour post administration, the animals were 
sacrificed and the tumor lysate was assayed for luciferase activity. The data demonstrated 
that a single dose (0.25mg/kg), IV injection of LHH-NP loaded with anti-luciferase siRNA 
resulted in a ~66% silencing of the target gene, significantly higher than that of LPH-NP 
mediated knockdown (34%) (Fig. 6d). The increased knockdown is most likely a result of 
the enhanced release of siRNA. The LHH-NP without targeting ligand was able to cause a 
~44% silencing, although there was no significant difference in the tumor accumulation of 
the targeted and non-targeted NPs. The results suggest that the presence of the targeting 
ligand probably facilitated the internalization of the NPs, which, in turn, promoted the 
siRNA delivery efficiency.
3.7. Systemic administration of LHH NP demonstrated minimal immune stimulating activity 
and negligible systemic toxicity
A panel of four cytokines, including IFN-α, TNF-α, IL-6 and IL-12, was assayed 4 h post-
administration of the LHH-NP (Fig. 7a). The results indicated the immunestimulating effects 
of the formulation. There was no detectable induction of IFN-α or IL-6. A mild elevation of 
TNF-α (~135pg/ml for LHH-NP and 123pg/ml for LPH-NP) was observed and a relatively 
high level IL-12 induction (~1278pg/ml for LHH-NP and 1310pg/ml for LPH-NP) was 
detected. However, there was not a significant difference between the treatment with LPH 
and LHH NPs regarding to the cytokine induction levels. The immunogenicity of TH was 
examined after repeated injection for three weeks and there was no TH-specific antibody 
detected (data not shown).
As was demonstrated by the biodistribution study, the liver and the kidneys were the two 
major organs that accumulated the most NPs in addition to the tumor. Therefore, it is 
necessary to check the liver and kidney infraction degree after the systemic administration of 
the LHH-NP. The serum alanine transaminase (ALT), aspartate transaminase (AST), liver 
damage markers, and blood urea nitrogen (BUN), a kidney infraction indicator, were 
examined after the mice received three injections of the NP (Fig. 7b). All parameters tested 
showed no significant difference between the treated group and the control group, which 
demonstrated that the NPs did not cause dysfunction of these two major organs.
4. Discussion
We have demonstrated that the use of a repetitive histone H2A peptide with intervening 
cathepsin D cleavage sites as a nucleic acid condensing agent to replace protamine in the 
LPH formulation, leads to an enhanced intracellular release of nucleic acid cargos after 
systemic administration. The enhanced release profile increased the intracellular 
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bioavailability of the cargo and effectively boosted the silencing efficiency of targeted 
siRNA delivery. Compared to synthetic, cationic polymers, such as polyamidoamine 
dendrimer, poly-(L-lysine) and polyethyleneimine [31–33] that are usually generated by the 
polymerization of a single unit, the building blocks for protein-based “biopolymers” are 
composed of 20 different amino acids and infinite patterns of combination. The number of 
combinations available allows more diverse physicochemical or biological functions of the 
biopolymers than the charge alone.
Nature affords us many examples that merit attention regarding the patterns of building 
blocks. For example, cell penetrating [34, 35], nuclear localization [36, 37], and cell-
targeting [38] sequences have been successfully incorporated into the design of many gene/
siRNA delivery carriers to increase their delivery efficiency and specificity. From a technical 
perspective, the advancement of technology in the molecular biology field enables the DNA 
templates with repetitive sequences to be synthesized with high efficiency, encoding longer 
biopolymers with arranged placements of building blocks, defined size, and stereochemistry 
[39]. The development of these biopolymers offers an attractive alternative for nucleic acid 
delivery because they are non-toxic, biodegradable and biocompatible when compared to 
their chemically synthetic counterparts.
In the present study, we exploited the N-terminal sequence of human histone H2A, which 
was able to deliver genes to the cells in vitro according to the report by Balicki et al. [19]. 
Similar to the low molecular weight synthetic cationic polymers, the histone-derived peptide 
(~4 KDa) did not provide sufficient binding affinity to condense the nucleic acid (Fig. 2c). 
For the core-membrane structure NPs, a solid core complex is necessary to support the lipid 
coating and extensive PEGylation, which allows extended blood circulation and tumor 
targeting of the NPs [40]. To compensate for the low binding affinity, we have multimerized 
the H2A peptides to enable the relatively higher molecular weight polypeptide (~24 kDa) to 
condense the nucleic acids to a degree approaching to that of protamine (Fig. 2c). Although 
the charge density in the biopolymer was much lower than that in chemical polymers, with 
only 19% of positively charged amino acids in the molecule, the two short α-helices 
interrupted by a short loop in each H2A peptide possibly allowed the biopolymer to anchor 
the nucleic acid strands and rendered higher binding affinity [19]. The structure-based 
binding in addition to electrostatic binding significantly reduced the requirement of positive 
charges in a condensing agent for complete condensation. This was beneficial to the 
development of safe siRNA delivery vectors, as material related cell death was often 
observed in the cationic polymeric condensing agents mediated transfection, such as 
polyethyleneimine or poly-(L-lysine). The mechanistic studies suggested that the 
electrostatic interaction between the polymers and mitochondria was the central mechanistic 
role for cell necrosis or apoptosis induced by the highly charged, cationic polymers [41]. 
Contrarily, the use of the biopolymer as condensing agent abolished the toxicity as 
demonstrated by the wide therapeutic window determined by MTS cytotoxicity assay (Fig. 
4b), possibly due to the relatively low charge-based reactivity and high degradability.
In order to facilitate the dissociation between the vectors and the nucleic acid cargos, 
cathepsin D cleavage sites were incorporated between H2A sequences as a switch for 
expedited degradation when exposed to the enzyme intracellularly. Cathepsin D is an 
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aspartic protease that is abundant in the endosomes of many cancer cells. The drop of pH in 
the endosome protonates the critical aspartate residue and activates the enzyme for 
sequence-specific cleavage of the substrate [42]. The incubation of TH-condensed NPs with 
cathepsin D could reverse the condensation of the complex as demonstrated by SYBR Green 
exclusion assay (Fig. 2d). A condensing agent that is stimulus-dependent and that induces 
reversible effects is the critical component of the design; it resolves the dilemma of poor 
condensing or poor release efficiency mediated by the traditional condensing agents.
The liposomal NP based on the core-membrane structure is a representative of NPs that have 
been designed to disassemble in a multistage manner after systemic administration (Fig. 8). 
The PEG coating and targeting ligand functionalize the surface of the liposomal membrane, 
allowing the NPs to be long-circulating in the blood stream and to efficiently accumulate in 
the interstitial space of tumor tissues. The targeting ligand grafted onto the surface of the 
NPs recognizes the tumor-specific receptors and facilitates the cellular internalization of the 
NPs. After endocytosis, the abundance of lipases in the endosomal compartment starts to 
strip the lipid coating, leaving the core complexes exposed to the environment of the 
endosomal compartment. The cathepsin D is activated accompanying the drop of pH in the 
endosome. The protease-mediated degradation of the condensing agent weakens its binding 
affinity to the nucleic acids. Simultaneously, the remaining cationic lipid forms ion-pair with 
lipid of compartmental membrane, which destabilizes the endosome. The pH-responsive, 
membrane-lytic peptide in the C-terminal of the TH offers an additional mechanism for the 
escape of the cargo. Once the loosened core complex enters the cytoplasm, the nucleic acids 
dissociates from condensing agent by charge-based competitive displacement with 
cytoplasmic proteins.
The data acquired from gene knockdown assay and biodistribution assay allowed us to 
establish a correlation between the in vitro and in vivo delivery efficiency of the 
nanoparticles. According to the biodistribution data from four-hour post-injection (Fig. 6c), 
the tumor accumulation of siRNA was approximately 5% injected dose per gram of tissue 
when 0.5 mg/kg siRNA was IV injected to the mice. Assuming the distribution pattern is 
applicable to the scenario of 0.25 mg/kg siRNA dose and that the local NP concentration 
remained constant in the tumor tissue for 24 hours post injection, there was approximately 
0.25 µg siRNA per gram of tissue. Given that the density of the tissue is 1.4 g/ml, the 
approximate concentration of siRNA was 26 nM on condition that the siRNA molecules 
were homogenously distributed over the whole tissue. However, NPs larger than 60 nm 
primarily accumulate in the interstitial space in the vicinity of the leaky vasculature, but are 
typically unable to penetrate deep into the tissue due to extracellular matrix and elevated 
interstitial pressure. Therefore, the effective dose of siRNA to the certain cell population 
under the influence was much higher than 26nM. Although our LHH formulation was able 
to achieve efficient siRNA delivery in vitro and in vivo, it was still difficult to directly 
predict in vivo delivery efficiency based on the in vitro data due to the complexity and 
heterogeneity of the tumor microenvironment.
This LHH NP was designed based on a solution-driven strategy. The knowledge of 
extracellular and intracellular NP trafficking routes as well as the understanding of the 
barriers to systemic delivery of siRNA leads to the recognition of problems, enabling us to 
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devise novel NPs with appropriate solutions. The NPs were engineered in an attempt to 
mimic lipid-enveloped viruses in terms of structure and delivery process, which are 
acknowledged as the most efficient gene delivery vectors in vivo. However, these NPs 
abrogate the high risk of immunogenic and oncogenic concerns raised when using viral 
vectors. Moreover, with relatively easy tunability of both the lipid coating and the 
biopolymer based condensing agent, these artificial virus-like gene delivery vectors are 
likely to catch up the performance of the viral particles, regarding the transfection ability, 
with minimal toxicity and immunogenicity.
5. Conclusion
We have successfully designed a histone derived recombinant protein with a reversible 
activity of capturing nucleic acid. The core formed by the engineered protein and nucleic 
acid can be further stabilized by lipid membrane coating and PEGylation. The biochemical 
studies validated the functionality of each designated motif in the molecule. The in vitro and 
in vivo transfection studies showed the enhanced delivery efficiency, which was likely to be 
attributed to the proposed mechanisms. Generally, the study demonstrated a strategy 
regarding to the enhancement of systemic siRNA delivery efficiency by manipulating the 
sequences of recombinant protein based condensing agent. It can be envisaged that more of 
these biopolymer-based materials will come up in the future studies of delivery of nucleic 
acid therapeutics.
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Figure 1. Expression and purification of TH biopolymer
a) Amino acid sequence of the TH. The recombinant, protein-based TH is composed of 
three functional motifs including condensation, dissociation and endosomal disruption motif, 
which are genetically engineered in one single molecule. b) SDS-PAGE analysis of purified 
TH followed by coomassie staining. The purity of the TH was estimated to be greater than 
95%. c) Western blot analysis with mouse anti-Histidine x6 antibody to identify the TH.
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Figure 2. The incorporation of multiple functional amino acid sequences in one molecule has 
preserved the functionality of each sequence
a) SDS-PAGE of digested TH with cathepsin D protease. Lane 1: ladder marker, Lane 2: 
undigested TH, lane 3: TH digested by cathepsin D. Lane 4: TH/ΔCathD digested by 
cathepsin D. Bottom chart: Quantification of relative amount of protein based on 
densitometry analysis. The incorporation of cathepsin D substrate in the TH facilitated the 
degradation in the presence of corresponding enzyme. b) Hemolysis activity of TH at acidic 
(pH=5.0) or neutral (pH=7.4) pH. 1% TritonX-100 was used as a positive control 
(representing 100% hemolysis) and buffer alone was used as a negative control (n=3). The 
endosome disruptive sequence, GALA, in the TH induced lysis of the membrane exclusively 
at an acidic pH. Error bars show mean ± s.d. Student t-test. c) SYBR Green exclusion assay. 
Plasmid DNA with SYBR Green I stain was complexed with protamine, H2A peptide 
(37mer) or TH at various N/P ratios. (n=3). TH-mediated DNA condensation was equivalent 
to that of protamine, whereas H2A could only condense DNA into a less compact degree. 
Error bars show mean ± s.d. d) Cathepsin D induced decondensation. Plasmid DNA was 
complexed with TH, TH/ΔCathD, H2A peptide and protamine at optimal N/P ratio, followed 
by cathepsin D incubation. The incorporation of cathepsin cleavage enabled the TH to 
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respond to the stimulus in a prompt way, facilitating the release of nucleic acids in an 
enzyme dependent manner.
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Figure 3. Preparation and characterization of LHH NP
a) Schematic illustration of LHH NP preparation. Anionic siRNA and HA is mixed with 
cationic TH and DOTAP/Cholesterol liposome to form the core-shell structure complex. The 
NP is then PEGylated through post-insertion by heating. b) Particle size and zeta potential 
characterization by Dynamic Light Scattering and Laser Doppler Velocimetry. c) TEM 
imaging of LHH NP after uranyl acetate staining. Scale bar: 100 nm.
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Figure 4. The AA functionalized LHH-NP has demonstrated cell targeting ability and low 
cytotoxicity
a) Ligand dependent knockdown of the target gene. LHH NPs with or without AA was 
loaded with siRNA against luciferase and administered to H460-luc cells. The knockdown 
efficiency was determined using a luciferase assay (n=3). The presence of AA on the surface 
of the NP significantly enhanced silencing efficiency. Error bars show mean ± s.d. Student t-
test. b): Dose-dependent cytotoxicity versus dose-dependent knockdown activity (n=3). 
Error bars show mean ± s.d. The LHH NP demonstrated minimal cytotoxicity even at a 
concentration 100 times higher than the IC50.
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Figure 5. The incorporation of TH into the LHH NP has demonstrated an enhanced intracellular 
release of the cargos and an increased siRNA silencing efficiency in vitro
a) Confocal microscopic observation of cytoplasmic distribution of FAM labeled dsODNs 
delivered by LHH-NPs or LPH-NP. Nucleus of the cells was stained with Hoechst (blue) and 
lysosomes were labeled with LysoTracker (red). dsODNs delivered by NPs composed of TH 
(image 1) and TH/ΔGALA (image 3) have displayed more homogenously dispersed pattern. 
However, the dsODNs delivered by the NPs composed of protamine (image 4) or TH/
ΔCathD (image 2) have demonstrated an aggregated pattern. b) Dose dependent luciferase 
knockdown activity of anti-luciferase siRNA when encapsulated in different NP 
formulations (n=3). The incorporation of TH in the NP formulation resulted in an enhanced 
target gene silencing efficiency compared with protamine. Error bars show mean ± s.d. c) 
IC50 of siRNA that is delivered by different NPs formulation, which was determined by the 
dose-response curve generated with Prism 5.0c software.
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Figure 6. The evaluation of biodistribution and transfection efficiency of the LHH-NP in vivo
a) Biodistribution profiles of Tex-red labeled dsODN in major organs of H460 xenograft 
bearing nude mice 4 h post-administration of LHH-NP. The NPs predominately accumulated 
in the liver, kidneys and tumors after IV injection. b) Confocal microscopic images of tumor 
cryosections after systemic delivery of LHH-NP encapsulating Texas-red labeled dsODNs. 
c) Quantification of LHH biodistribution by tracking 3H labeled dsODNs 4 h post-injection 
(n=3). There was ~5% injected dose per gram tissue accumulated in the tumor. Error bars 
show mean ± s.d. d) In vivo luciferase gene silencing effects 24 h after IV injection of LHH 
and LPH NPs to the H460-luc bearing nude mice (0.25mg/kg) (n=3). siRNA delivered by 
LHH-NP resulted in significantly higher silencing effect than that of LPH-NP. Error bars 
show mean ± s.d. Student t-test.
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Figure 7. The evaluation of immunostimulating effect and systemic toxicity of the LHH-NP
a) Serum cytokine levels of the LHH-NP and the LPH-NP treated CD-1 mice examined by 
ELISA assay. A slight increase of TNF-α and relatively high level of IL12 was observed 
after injection. No significant difference was observed between LHH and LPH treatments. 
Error bars show mean ± s.d. b) AST, ALT and BUN levels of CD-1 mice after repeated 
injections (3 times × 0.5mg/kg) of LHH-NP. The repeated treatments of LHH-NP didn’t 
incur liver and kidney damage according to the blood biochemistry tests.
Wang et al. Page 24













Figure 8. Schematic illustration of proposed LHH NP intracellular trafficking after systemic 
delivery
i. The pegylated LHH NP shows extended blood circulation by evading the capture of 
reticuloendothelial system and extravsates into the interstitial space of the tumor due to the 
EPR effect. ii. The targeting ligand at the distal end of the PEG facilitates the cellular 
internalization of the NPs. iii, the NPs are entrapped in the endosomal compartment where 
the pH starts to drop. The lipase will strip the lipid membrane and the core is exposed to pH-
activated cathepsin D enzyme. iv. The cationic lipid starts to destabilize the membrane 
structure due to the ion-exchange mechanism. Meanwhile, the pH-activated GALA peptide 
inserts into the compartment membrane and forms the barrel structure in the membrane to 
release endosome. v. After endosome escape, the degraded TH by cathepsin D demonstrates 
weakened binding affinity to the nucleic acids, leaving the anionic cargos to be easily 
released by the charge-based competitive displacement.
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